Womed Leaf
Womed Sas · Decision date Oct 25, 2026
What did the FDA approve?
The FDA database entry for P240015/S003, dated 2026-10-25, records an approval of a real-time process supplement from Womed Sas. Supplement type is listed as Real-Time Process, and the supplement reason field cites labeling change covering indications, instructions, shelf life, or tradename. The source statement describes the action as being for labeling changes to reduce the chance of product expulsion. The device sits in the absorbable adhesion barrier category, obstetrics/gynecology specialty, product code MCN, titled Womed Leaf.
The supplement number establishes a link to parent PMA P240015, but this record covers only the supplement, not a fresh approval of the whole system. The stated purpose of reducing expulsion risk is the applicant's or reviewer's reported aim for the labeling change, not independent proof of safety or clinical effectiveness. The entry does not specify which labeling element changed, the prior wording, test data, or the mechanism by which expulsion risk would be reduced; those details are absent from the supplied fields.
FDA approval order statement
for labeling changes to reduce the chance of product expulsion
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Oct 25, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240015/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Womed Sas
- Product code
- MCN
- Decision code
- APPR
- Decision date
- Oct 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, absorbable, adhesion.
For the original device and its historical approval scope, see PMA P240015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240015 · Original PMA
Womed Leaf Resorbable Adhesion Barrier
P240015/S003 received
Application receipt date recorded by FDA.
P240015/S003 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240015
Explore the linked device profile
Other records with product code MCN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S072 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Juveena Hydrogel SystemP250051/S001 | Rejoni, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Juveena Hydrogel SystemP250051 | Rejoni, Inc. | PMA approval | Sep 28, 2026 | FDA |
| ETHICON, Inc. | PMA approval | Sep 15, 1989 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Womed Sas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Batiment Balard Cit, 1919 Rte. De Mende, Montpellier, 34090
Sources and methodology
- Original FDA record: P240015/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

